参考文献/References:
［1］ 中华医学会感染病学分会,华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)［J］.实用肝脏病杂志,2020,23(1):S9-S32.
CHINESE SOCIETY OF INFECTIOUS DISEASES,CHINESE MEDICAL ASSOCIATION,CHINESE SOCIETY OF HEPATOLOGY,CHINESE MEDICAL ASSOCIATION.The guidelines of prevention and treatment for chronichepatitis B(2019 version)［J］.Chin J Hepatol,2020,23(1):S9-S32.
［2］ QI W Q,ZHANG Q,XU Y,et al.Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation［J］.J Viral Hepat,2020,27(4):387-396.
［3］ FRIEDRICH S K,LANG P A,FRIEBUS-KARDASH J,et al.Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease［J］.Clin Exp Immunol,2019,195(1):64-73.
［4］ GUIDOTTI L G,ISOGAWA M,CHISARI F V.Host-virus interactions in hepatitis B virus infection［J］.Curr Opin Immunol,2015,36:61-66.
［5］ MILLING S.Sophisticated specificity in the innate immune response［J］.Immunology,2019,158(2):61-62.
［6］ MENG Z,CHEN Y,LU M.Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection［J］.Front Immunol,2020,10:3127.
［7］ ZENG Y,WU W,FU Y,et al.Toll-like receptors,long non-coding RNA NEAT1,and RIG-I expression are associated with HBeAg-positive chronic hepatitis B patients in the active phase［J］.J Clin Lab Anal,2019,33(5):e22886.
［8］ YE S,ZHANG X,ZHANGYB,et al.Association of TLR3 (rs3775291) and IL-10 (rs1800871) gene polymorphisms with susceptibility to hepatitis B infection:a meta-analysis［J］.Epidemiol Infect,2020,148:e228.
［9］ TEIXEIRA H S,ZHAO J,KAZMIERSKI E,et al.TLR3-dependent activation of TLR2 endogenous ligands via the MyD88 signaling pathway augments the innate immune response［J］.Cells,2020,9(8):1910.
［10］ ISOGAWA M,ROBEK M D,FURUICHI Y,et al.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo［J］.J Virol,2005,79(11):7269-7272.
［11］ BROERING R,LU M,SCHLAAK J F.Role of toll-like receptors in liver health and disease［J］.Clin Sci(Lond),2011,121(10):415-426.
［12］ PAULSEN D,WEBER O,RUEBSAMEN-SCHAEFF H,et al.AIC649 induces a bi-phasic treatment response in the woodchuck model of chronic hepatitis B［J］.PLoS One,2015,10(12):144383.
［13］ GANE E J,LIM Y S,GORDAN S C,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection［J］.J Hepatol,2015,63(2):320-328.
［14］ DU K,LIU J,BROERING R,et al.Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections［J］.Expert Opin Drug Discov,2018,13(7):661-670.
［15］ HU Y,TANG L,ZHU Z,et al.A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model［J］.J Transl Med,2020,18(1):112.
［16］ BERTOLETTI A,LE BERT N.Fine-tuning TLR-7-based therapy for functional HBV cure［J］.Hepatol Commun,2019,3(10):1289-1292.
［17］ HU Y,ZHANG H,WU M,et al.Safety,pharmacokinetics and pharmacodynamics of TQ-A3334,an oral toll-like receptor 7 agonist in healthy individuals［J］.Expert Opin Investig Drugs,2021,30(3):263-269.
［18］ MOSSAD Y M,METWALLY S S,FARAG R E,et al.Association between toll-like receptor 3 (TLR3) rs3775290,TLR7 rs179008,TLR9 rs352140 and chronic HCV［J］. Immunol Invest,2019,48(3):321-332.
［19］ DOYLE S E,SCHRECKHISE H,KHUU-DUONG K,et al.Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes［J］. Hepatology,2006,44(4):896-906.
［20］ MIELCARSKA M B,BOSSOWSKA-NOWICKA M,GREGORCZYK-ZBOROCH K P,et al.Syk and Hrs regulate TLR3-mediated antiviral response in murine astrocytes［J］.Oxid Med Cell Longev,2019,2019:6927380.
［21］ KAYESH M E H,KOHARA M,TSUKIYAMA-KOHARA K.Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B:anoverview［J］.Int J Mol Sci,2021,22(19):10462.
［22］ CHIAPPINELLI K B,STRISSEL P L,DESRICHARD A,et al.Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses［J］.Cells,2015,162(5):974-986.
［23］ ASADI-ASADABAD S,SARVNAZ H,AMIRI M M,et al.Influence of pattern recognition receptor ligands on induction of innate immunity and control of hepatitis B virus infection［J］.Viral Immunol,2021,34(8):531-541.
［24］ SEYA T,TAKEDA Y,MATSUMOTO M.Atoll-like receptor 3(TLR3)agonist ARNAX for therapeutic immunotherapy［J］.Adv Drug Deliv Rev,2019,147:37-43.
［25］ JIN M,KOMINE M,TSUDA H,et al.dsRNA induces IL-33 promoter activity through TLR3-EGFR-IRF3 pathway in normal human epidermal keratinocytes［J］.J Dermatol Sci,2019,96(3):178-180.
［26］ LEBOSS F,TESTONI B,FRESQUET J,et al.Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B［J］.J Hepatol,2017,66(5):897-909.
［27］ THOMPSON A J,NGUYEN T,ISER D,et al.Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers［J］.Hepatology,2010,51(6):1933-1944.
［28］ MANESIS E K,PAPATHEODORIDIS G V,TINIAKOSD G,et al.Hepatitis B surface antigen:relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B［J］.J Hepatol,2011,55(1):61-68.
［29］ REAL C I,LU M,LIU J,et al.Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen［J］.Sci Rep,2016,6:24865.
［30］ YUAN M M,XU Y Y,CHEN L,et al.TLR3 expression correlates with apoptosis,proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis ［J］.BMC Cancer,2015,15:245.
［31］ GENG P L,SONG L X,AN H,et al.Toll-like receptor 3 is associated with the risk of HCV infection and HBV-related diseases［J］.Medicine(Baltimore),2016,95(21):e2302.
［32］ HO V,LIM T S,LEE J,et al.TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression［J］.Oncotarget,2015,6(29):27252-27266.
［33］ BONNIN M,FARES N,TESTONI B,et al.Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis［J］.J Hepatol,2019,71(4):763-772.
［34］ SGHAIER I,ZIDI S,MOUELHI L,et al.TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection［J］.Br J Biomed Sci,2019,76(1):35-41.
相似文献/References:
[1]许世琴,张倩,高同举.荧光定量聚合酶链反应检测乙肝病毒DNA的临床意义[J].新乡医学院学报,2001,18(04):292.
[2]焦栓林,许丽芝,申德林,等.拉米夫定治疗慢性乙型肝炎过程中的YMDD变异及其临床意义[J].新乡医学院学报,2002,19(06):465.
[3]焦栓林,许丽芝,申德林,等.拉米夫定治疗慢性乙型肝炎过程中的YMDD变异及其临床意义[J].新乡医学院学报,2002,19(06):465.
[4]许德军,李太平,郎振为.巨细胞病毒在慢性乙型肝炎患者肝组织中的表达[J].新乡医学院学报,2006,23(05):529.
[5]卫萍,成军,楚庸烈,等.应用酵母双杂交技术筛选与前S1蛋白反式激活蛋白3结合的肝细胞蛋白基因 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):329.
[6]陈占军,丁小华,裴 容,等.综合护理干预对老年乙型肝炎肝硬化合并２型糖尿病患者的影响[J].新乡医学院学报,2014,31(05):405.[doi:10.7683/xxyxyxb.2014.05.026]
[7]叶 明.2种方案阻断乙型肝炎病毒母婴传播效果比较[J].新乡医学院学报,2014,31(11):915.[doi:10.7683/xxyxyxb.2014.11.014]
[8]赵佳,尚文会,田召兵,等.不同商品化试剂盒定量检测肝癌晚期患者乙型肝炎病毒 DNA结果的差异[J].新乡医学院学报,2022,39(12):1155.[doi:10.7683/xxyxyxb.2022.12.010]
ZHAO Jia,SHANG Wenhui,TIAN Zhaobing,et al.Difference of quantitative detection of hepatitis B virus DNA in patients with advanced liver cancer by different commercial kits[J].Journal of Xinxiang Medical University,2022,39(4):1155.[doi:10.7683/xxyxyxb.2022.12.010]
[9]王天宝,王 扬,罗 磊,等.乙型肝炎病毒与戊型肝炎病毒重叠感染患者T淋巴细胞变化及相关临床危险因素分析[J].新乡医学院学报,2018,35(11):1013.[doi:10.7683/xxyxyxb.2018.11.017]
WANG Tian-bao,WANG Yang,LUO Lei,et al.Analysis of T lymphocyte changes and related clinical risk factors in patients with hepatitis B virus and hepatitis E virus superinfection[J].Journal of Xinxiang Medical University,2018,35(4):1013.[doi:10.7683/xxyxyxb.2018.11.017]
[10]王树俊,孙会潇,徐 侠,等.去甲斑蝥素片联合替诺福韦酯治疗失代偿期肝硬化疗效观察[J].新乡医学院学报,2021,38(5):458.[doi:10.7683/xxyxyxb.2021.05.013]
WANG Shujun,SUN Huixiao,XU Xia,et al.Effect of norcantharidin tablets combined with tenofovir disoprox in the treatment of decompensated cirrhosis[J].Journal of Xinxiang Medical University,2021,38(4):458.[doi:10.7683/xxyxyxb.2021.05.013]